RxDoctor Payments Data

Carolyn le, PA

Physician Assistant · Irvine, CANPI 1477212728

Payments from drug & device makers

$9,342in general payments, 2019–2025

Across 454 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$638
  • Johnson & Johnson$625
  • Alkermes, Inc.$620
  • plus $3K from 16 others

What the payments were for

  • Food & beverage$9,21899%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,342 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$11,041
Medicare patients
26
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$45,854
TrintellixVortioxetine Hydrobromide57$28,859
RexultiBrexpiprazole13$22,271
Lurasidone Hcl14$6,395
Mirtazapine31$1,288
Divalproex Sodium ErDivalproex Sodium23$1,074
Benztropine Mesylate33$572
Bupropion XlBupropion Hcl39$557
Fluvoxamine Maleate11$530
Quetiapine Fumarate36$486
Duloxetine Hcl24$407
Doxepin Hcl13$361
Gabapentin36$302
Propranolol Hcl34$301
Methylphenidate Hcl15$271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$625$45,85413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$162$28,85957 claims
Otsuka America Pharmaceutical, Inc.Rexulti$486$22,27113 claims
Almatica Pharma LLCSertraline Hcl$297$15836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →